Tectonic Therapeutic Announces Closing of Merger with AVROBIO as well as Concurrent Private Placement of $130.7 Million
Tectonic Therapeutic has completed a merger with AVROBIO and a $130.7 million private placement. The company now operates as Tectonic Therapeutic, trading on Nasdaq under ticker symbol 'TECX' starting June 21, 2024. The merger gives Tectonic approximately $181 million in cash and investments to fund operations until mid-2027. Tectonic's lead program, TX45, is in Phase 1 trials for treating Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction, with Phase 2 trials expected in 2026. Another program targets Hereditary Hemorrhagic Telangiectasia. AVROBIO shareholders received a contingent value right for certain cash payments related to AVROBIO’s legacy assets.
- Successful merger completion with AVROBIO.
- Raised $130.7 million in a private placement.
- Trades on Nasdaq under 'TECX' starting June 21, 2024.
- Approximately $181 million in cash and investments.
- Funds expected to last until mid-2027.
- Upcoming key clinical trial milestones for TX45 and HHT programs.
- Strong investor syndicate including TAS Partners, 5AM Ventures, and others.
- Previous AVROBIO shareholders now hold only 24.8% of the combined company.
- Potential dilution of shares due to 1 for 12 reverse stock split.
- Final transaction-related expenses not yet deducted from available funds.
The merger between Tectonic Therapeutic and AVROBIO, along with the substantial
The stock split and the subsequent issuance of contingent value rights (CVRs) aimed at AVROBIO shareholders are also important. Stock splits can sometimes be perceived negatively, but the CVRs provide a potential upside tied to the disposition of AVROBIO’s legacy assets, which could appease existing shareholders.
Equity distribution post-merger shows Tectonic shareholders holding a substantial majority which indicates confidence from existing stakeholders and strategic investors. These elements suggest a positive trajectory for Tectonic, though investors should watch milestones, such as clinical trial results closely.
Rating: 1
Tectonic’s focus on GPCR-targeted therapies, particularly TX45 for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (HFpEF), is noteworthy. HFpEF represents a significant unmet medical need, with over 600,000 affected individuals in the U.S. alone. The advancement into Phase 2 trials and the expected readouts from Phase 1a and 1b trials over the next few years will be key inflection points.
Similarly, the program targeting Hereditary Hemorrhagic Telangiectasia (HHT) potentially offers a first-in-class treatment for a genetic bleeding disorder affecting around 70,000 people in the U.S. These therapeutic areas, if successful, could provide substantial clinical and commercial benefits. Investors should pay attention to the clinical trial timelines and outcomes, as they will significantly influence the company's valuation and prospects.
Rating: 1
The merger and subsequent positioning on the Nasdaq under the ticker 'TECX' reflects a strategic move to enhance visibility in the public markets. The involvement of prominent investment firms such as 5AM Ventures and EcoR1 Capital in the private placement indicates strong confidence from seasoned investors. This endorsement is a positive signal for potential retail investors considering an entry point.
The dual focus on rare diseases with high unmet needs and the strategic financial backing until mid-2027 provides a solid groundwork for Tectonic's market presence. The investor should note the significant milestones expected over the next few years and how these align with market dynamics and regulatory landscapes.
Rating: 1
- Tectonic will be focused on advancing a pipeline of novel G-protein-coupled receptor (“GPCR”) targeted biologic therapies, including the lead program, TX45, a Fc-relaxin fusion
-
TX45 is currently being evaluated in Phase 1a/1b clinical trials as a potential treatment for Group 2 Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (“HFpEF”), a serious condition estimated to affect over 600,000 people in the
U.S. alone, currently with no approved therapies - Tectonic’s second program is evaluating Hereditary Hemorrhagic Telangiectasia (“HHT”), the second-most common genetic bleeding disorder, representing a potential first-in-indication opportunity
-
Post-transaction cash, cash equivalents and investments of approximately
$181 million - Shares to trade on Nasdaq under the ticker symbol "TECX" commencing on June 21, 2024
Concurrent with the merger, Tectonic completed a
"It's an exciting time to be transitioning into a publicly-traded company. We expect to initiate a randomized Phase 2 clinical trial for our lead program, TX45, in Group 2 Pulmonary Hypertension in the setting of Left Heart Disease with Preserved Ejection Fraction in the second half of this year. Results from the ongoing Phase 1a clinical trial in this patient population are expected in mid-2024, to be followed by Phase 1b results expected in 2025 and results from the Phase 2 clinical trial expected in 2026. We also expect to select a potential development candidate for our second program targeting a treatment for HHT, later this year, with the start of corresponding clinical studies anticipated to commence in the fourth quarter of 2025 or the first quarter of 2026," said Alise Reicin, M.D., President and Chief Executive Officer of Tectonic.
"We believe we are strongly positioned to enter the public markets at this time, with a solid financial foundation, investor syndicate and leadership team, and with several potential catalysts over the next two years, setting the stage for meaningful value creation. This transaction represents a major milestone in the evolution of Tectonic and in our efforts to bring innovative medicines to patients,” added Dr. Reicin.
Tectonic’s lead program, TX000045 (“TX45”), is an Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone relaxin. Tectonic believes TX45’s pharmacological profile, the direct result of applying Tectonic’s protein engineering capabilities, has the potential to overcome the limitations that have impeded previous attempts to develop relaxin as a therapeutic protein.
Tectonic’s second program addresses Hereditary Hemorrhagic Telangiectasia (“HHT”), the second-most common genetic bleeding disorder. It has been estimated that there are approximately 70,000 HHT patients in
Transaction Details
In connection with the closing of the merger, AVROBIO enacted a 1 for 12 reverse stock split of its common stock and issued a non-transferable contingent value right (a "CVR") to AVROBIO shareholders of record immediately prior to the closing, which does not include the former holders of shares of Tectonic or the private placement investors. Holders of a CVR will be entitled to receive certain cash payments from proceeds received by Tectonic, if any, related to the dispositions of AVROBIO’s pre-transaction legacy assets. Following the reverse stock split and based on the final exchange ratio of approximately 0.5344 shares of AVROBIO common stock for each share of Tectonic common stock, at the closing of the merger, there are approximately 15,371,780 shares of the combined company's common stock outstanding on a diluted basis, with prior AVROBIO stockholders owning approximately
Leerink Partners served as exclusive financial advisor to Tectonic and Cooley LLP served as legal counsel to Tectonic. Leerink Partners and TD Cowen acted as joint placement agents for Tectonic’s private placement. Piper Sandler acted as capital markets advisor to Tectonic. TD Cowen served as lead financial advisor to AVROBIO, Houlihan Lokey served as co-financial advisor to AVROBIO, and Goodwin Procter LLP served as legal counsel to AVROBIO.
About Tectonic
Tectonic Therapeutic is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of G-protein coupled receptors (“GPCRs”). Leveraging its proprietary technology platform called GEODe™ (“GPCRs Engineered for Optimal Discovery”), Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery and harness the human body to modify the course of disease. Tectonic focuses on areas of significant unmet medical need, often where therapeutic options are poor or nonexistent, as these are areas where new medicines have the potential to improve patient quality of life. Tectonic is headquartered in
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. All statements in this press release other than statements of historical facts are “forward-looking statements. These statements may be identified by words such as “aims,” “anticipates,” “believes,” “could,” “estimates,” “expects,” “forecasts,” “goal,” “intends,” “may,” “plans,” “possible,” “potential,” “seeks,” “will” and variations of these words or similar expressions that are intended to identify forward-looking statements, although not all forward-looking statements contain these words. Forward-looking statements in this press release include, but are not limited to, statements regarding: the design, objectives, initiation, timing, progress and results of current and future preclinical studies and clinical trials of Tectonic’s product candidates, including the ongoing Phase 1a/b clinical trial for its lead program, TX45, in Group 2 Pulmonary Hypertension and initiation of Phase 2 clinical trial; candidate selection for Tectonic’s second program in HHT; market opportunity and Tectonic’s anticipated cash runway. These forward-looking statements are based on Tectonic’s expectations and assumptions as of the date of this press release. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond Tectonic’s control. Actual results and the timing of events could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: (i) the ability of AVROBIO and Tectonic to integrate their businesses successfully and to achieve anticipated synergies; (ii) the possibility that other anticipated benefits of the merger will not be realized, including without limitation, anticipated revenues, expenses, earnings and other financial results, and growth and expansion of Tectonic’s operations, and the anticipated tax treatment of the merger; (iii) potential litigation relating to the transaction that could be instituted against Tectonic or its directors; (iv) the ability of Tectonic to retain, attract and hire key personnel; (v) potential adverse reactions or changes to relationships with customers, employees, suppliers or other parties resulting from the completion of the transaction; (vi) potential business uncertainty, including changes to existing business relationships that could affect Tectonic’s financial performance; (vii) Tectonic’s need for additional funding, which may not be available; (viii) failure to identify additional product candidates and develop or commercialize marketable products; (ix) the early stage of Tectonic’s development efforts; (x) potential unforeseen events during clinical trials could cause delays or other adverse consequences; (xi) risks relating to the regulatory approval process; (xii) interim, topline and preliminary data may change as more patient data become available, and are subject to audit and verification procedures that could result in material changes in the final data; (xiii) success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate; (xiv) Tectonic’s product candidates may cause serious adverse side effects; (xv) inability to maintain its collaborations, or the failure of these collaborations; (xvi) Tectonic’s reliance on third parties, including for the manufacture of materials for its research programs, preclinical and clinical studies; (xvii) failure to obtain
View source version on businesswire.com: https://www.businesswire.com/news/home/20240620882931/en/
Investors:
Dan Ferry
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
Media:
Karen Sharma
CG Life
ksharma@cglife.com
(617) 571-2733
Source: Tectonic Therapeutic
FAQ
What is the ticker symbol for Tectonic Therapeutic after the merger with AVROBIO?
How much did Tectonic Therapeutic raise in the private placement?
When will Tectonic Therapeutic start trading on Nasdaq?
What is the focus of Tectonic Therapeutic's lead program TX45?
How long is Tectonic Therapeutic funded for post-merger?
What are the key upcoming milestones for Tectonic Therapeutic’s clinical trials?
What percentage of the combined company's outstanding common stock do prior Tectonic stockholders hold?
